Candriam S.C.A. Sells 18,211 Shares of Elevance Health, Inc. $ELV

Candriam S.C.A. lowered its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 27.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,258 shares of the company’s stock after selling 18,211 shares during the quarter. Candriam S.C.A.’s holdings in Elevance Health were worth $15,916,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Physician Wealth Advisors Inc. boosted its holdings in Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares during the period. Activest Wealth Management lifted its position in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the period. Vermillion & White Wealth Management Group LLC lifted its position in Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares during the period. BOK Financial Private Wealth Inc. bought a new position in shares of Elevance Health during the 2nd quarter worth about $32,000. Finally, Motco boosted its holdings in Elevance Health by 334.8% during the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after purchasing an additional 77 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ELV. Barclays cut their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. The Goldman Sachs Group assumed coverage on Elevance Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price target on the stock. UBS Group set a $400.00 target price on Elevance Health in a report on Thursday, January 29th. Truist Financial cut their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Finally, Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Trading Down 3.7%

ELV opened at $326.44 on Tuesday. The firm’s fifty day simple moving average is $351.97 and its 200 day simple moving average is $331.02. The stock has a market capitalization of $72.55 billion, a P/E ratio of 13.00, a P/E/G ratio of 1.89 and a beta of 0.50. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same period in the previous year, the company posted $3.84 earnings per share. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is presently 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.